Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 12, Issue 1 (Vol.12 No.1 Apr 2023)
rbmb.net 2023, 12(1): 120-126 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rajabi A, Dastmalchi N, Shokri N, Tayefeh-Gholami S, Yaghobi S M, Safaralizadeh R. Expression Level of lncRNA CYTOR in Iranian Cervical Cancer Patients. rbmb.net 2023; 12 (1) :120-126
URL: http://rbmb.net/article-1-1110-en.html
URL: http://rbmb.net/article-1-1110-en.html
Ali Rajabi 
, Narges Dastmalchi , Neda Shokri , Samaneh Tayefeh-Gholami , Seyyed Mohammad Yaghobi , Reza Safaralizadeh *
, Narges Dastmalchi , Neda Shokri , Samaneh Tayefeh-Gholami , Seyyed Mohammad Yaghobi , Reza Safaralizadeh *
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Abstract: (1440 Views)
Background: A critical role has been known for lncRNAs in the initiation and development of cancers. Therefore, lncRNAs have been reported as the possible biomarkers in relation to the diagnosis and therapy of malignancies. This project examined the change in CYTOR lncRNA expression in human cervical cancer samples as compared with adjacent healthy ones.
Methods: We provided one hundred fifteen pairs of tumorous and adjacent healthy tissue specimens of cervical cancer patients. RNAs were isolated from tissue specimens and cDNAs were synthesized. We considered quantitative Real-time PCR (qRT-PCR) to examine the expression levels of CYTOR lncRNA. In addition, the biomarker activity of CYTOR and the associations between the lncRNA and clinicopathological characteristics were evaluated.
Results: The significant increased expression of CYTOR was obtained in cancerous samples as compared with non-cancerous ones (P< 0.0001). A significant correlation was indicated between CYTOR expression and the squamous subtype of cervical cancer (p=0.046). The receiver operating characteristic (ROC) curve-related AUC (area under the curve), specificity, and sensitivity were calculated 0.88, 81.74%, and 80%, respectively, which may introduce CYTOR as a potential biomarker.
Conclusions: CYTOR may be an effective oncogene and biomarker in cervical cancer cases given its increased expression in human cervical cancer tissues.
Methods: We provided one hundred fifteen pairs of tumorous and adjacent healthy tissue specimens of cervical cancer patients. RNAs were isolated from tissue specimens and cDNAs were synthesized. We considered quantitative Real-time PCR (qRT-PCR) to examine the expression levels of CYTOR lncRNA. In addition, the biomarker activity of CYTOR and the associations between the lncRNA and clinicopathological characteristics were evaluated.
Results: The significant increased expression of CYTOR was obtained in cancerous samples as compared with non-cancerous ones (P< 0.0001). A significant correlation was indicated between CYTOR expression and the squamous subtype of cervical cancer (p=0.046). The receiver operating characteristic (ROC) curve-related AUC (area under the curve), specificity, and sensitivity were calculated 0.88, 81.74%, and 80%, respectively, which may introduce CYTOR as a potential biomarker.
Conclusions: CYTOR may be an effective oncogene and biomarker in cervical cancer cases given its increased expression in human cervical cancer tissues.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2022/12/13 | Accepted: 2023/01/22 | Published: 2023/08/15
Received: 2022/12/13 | Accepted: 2023/01/22 | Published: 2023/08/15
References
1. Rezai M, Saravani R, Sargazi S, Moudi M, Jafari Shahroudi M, Saravani R. Achillea Wilhelmsii C. KochHydroalcoholic Extract Induces Apoptosis and Alters LIN28B and p53 Gene Expression in Hela Cervical Cancer Cells. Rep Biochem Molecul Biol. 2019;8(3):318-25.
2. Ward ZJ, Grover S, Scott AM, Woo S, Salama DH, Jones EC, et al. The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. Lancet Oncol. 2020;21(8):1089-98.
https://doi.org/10.1016/S1470-2045(20)30316-8 [DOI:10.1016/S1470-2045(20)30317-X] [PMID]
3. Lagana AS, Garzon S, Raffaelli R, Ban Frangez H, Lukanovic D, Franchi M. Vaginal Stenosis After Cervical Cancer Treatments: Challenges for Reconstructive Surgery. J Invest Surg. 2021;34(7):754-5. [DOI:10.1080/08941939.2019.1695987] [PMID]
4. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169-82. [DOI:10.1016/S0140-6736(18)32470-X] [PMID]
5. Liu YM, Ni LQ, Wang SS, Lv QL, Chen WJ, Ying SP. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study. World J Surg Oncol. 2018;16(1):18. [DOI:10.1186/s12957-017-1307-0] [PMID] [PMCID]
6. Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int. 2013;2013:519619. [DOI:10.1155/2013/519619] [PMID] [PMCID]
7. Agnihotri SK, Kumar B, Jain A, Anjali A, Negi MPS, Sachan R, et al. Clinical Significance of Circulating Serum Levels of sCD95 and TNF-α in Cytoprotection of Cervical Cancer. Rep Biochem Mol Biol. 2022;10(4):711-21. [DOI:10.52547/rbmb.10.4.711] [PMID] [PMCID]
8. Onyango CG, Ogonda L, Guyah B, Shiluli C, Ganda G, Orang'o OE, et al. Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review. Infect Agent Cancer. 2020;15(1):1-12. [DOI:10.1186/s13027-020-00335-2] [PMID] [PMCID]
9. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143-57. [DOI:10.1038/nrm.2017.104] [PMID] [PMCID]
10. Ahmad I, Valverde A, Ahmad F, Naqvi AR. Long Noncoding RNA in Myeloid and Lymphoid Cell Differentiation, Polarization and Function. Cells. 2020;9(2). [DOI:10.3390/cells9020269] [PMID] [PMCID]
11. Aalijahan H, Ghorbian S. Long non-coding RNAs and cervical cancer. Exp Mol Pathol. 2019;106:7-16. [DOI:10.1016/j.yexmp.2018.11.010] [PMID]
12. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96-118.
https://doi.org/10.1038/s41580-020-00315-9 [DOI:10.1038/s41580-021-00330-4] [PMID] [PMCID]
13. Rajabi A, Bastani, S., Maydanchi, M. et al. Moderate Prognostic Value of lncRNA FOXD2-AS1 in Gastric Cancer with Helicobacter pylori Infection. J Gastrointest Cancer. 2021. [DOI:10.1007/s12029-021-00686-y] [PMID]
14. Rajabi A, Riahi A, Shirabadi-Arani H, Moaddab Y, Haghi M, Safaralizadeh R. Overexpression of HOXA-AS2 LncRNA in Patients with Gastric Cancer and Its Association with Helicobacter pylori Infection. J Gastrointest Cancer. 2020. [DOI:10.1007/s12029-020-00549-y] [PMID]
15. Riahi A, Hosseinpour-Feizi M, Rajabi A, Akbarzadeh M, Montazeri V, Safaralizadeh R. Overexpression of long non-coding RNA MCM3AP-AS1 in breast cancer tissues compared to adjacent non-tumour tissues. Br J Biomed Sci. 2021;78(2):53-7. [DOI:10.1080/09674845.2020.1798058] [PMID]
16. He J, Huang B, Zhang K, Liu M, Xu T. Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity. Biomed Pharmacother. 2020;127:110209. [DOI:10.1016/j.biopha.2020.110209] [PMID]
17. Behzadi S, Baradaran B, Hosseinpourfeizi MA, Dastmalchi N, Rajabi A, Asadi M, et al. BC032913 as a Novel Antisense Non-coding RNA is Downregulated in Gastric Cancer. J Gastrointest Cancer. 2021;52(3):928-31. [DOI:10.1007/s12029-020-00517-6] [PMID]
18. Xu Y, Qiu M, Shen M, Dong S, Ye G, Shi X, et al. The emerging regulatory roles of long non-coding RNAs implicated in cancer metabolism. Mol Ther. 2021;29(7):2209-18. [DOI:10.1016/j.ymthe.2021.03.017] [PMID] [PMCID]
19. Chen S, Shen X. Long noncoding RNAs: functions and mechanisms in colon cancer. Mol Cancer. 2020;19(1):167. [DOI:10.1186/s12943-020-01287-2] [PMID] [PMCID]
20. Tan H, Zhang S, Zhang J, Zhu L, Chen Y, Yang H, et al. Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications. Theranostics. 2020;10(19):8880-902. [DOI:10.7150/thno.47548] [PMID] [PMCID]
21. Sun C, Zhou Z, Shi H, Li F, Zhang G. Identification of Long Noncoding RNA APOC1P1 as an Oncogene in Clear Cell Renal Cell Carcinoma. Dis Markers. 2019;2019:2814058. [DOI:10.1155/2019/2814058] [PMID] [PMCID]
22. Naghashi N, Ghorbian S. Clinical important dysregulation of long non-coding RNA CCHE1 and HULC in carcinogenesis of cervical cancer. Mol Biol Rep. 2019;46(5):5419-24. [DOI:10.1007/s11033-019-04996-0] [PMID]
23. Jannat Alipoor F, ASADI MH, TORKZADEH MAHANI M. LncRNA MIAT Promotes Proliferation of Cervical Cancer Cells and Acts as an Anti-apoptotic Factor. J Biochem. 2017;3(2):-.
24. Chen QN, Chen X, Chen ZY, Nie FQ, Wei CC, Ma HW, et al. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression. Mol Cancer. 2017;16(1):17. [DOI:10.1186/s12943-017-0581-3] [PMID] [PMCID]
25. Sun Z, Guo X, Zang M, Wang P, Xue S, Chen G. Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis. J Cell Physiol. 2019;234(2):1336-45. [DOI:10.1002/jcp.26928] [PMID]
26. Zhang Y, Jin W, Ma D, Cao J, Fu T, Zhang Z, et al. Long non-coding RNA CYTOR regulates proliferation and metastasis of colon cancer cells through regulating miRNA-105/PTEN axis. Int J Clin Exp Pathol. 2021;14(4):434-43.
27. Liu Y, Li M, Yu H, Piao H. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR125a5p. Int J Mol Med. 2020;45(2):497-509. [DOI:10.3892/ijmm.2019.4428]
28. Wei F, Wang Y, Zhou Y, Li Y. Long noncoding RNA CYTOR triggers gastric cancer progression by targeting miR-103/RAB10. Acta Biochim Biophys Sin (Shanghai). 2021;53(8):1044-54. [DOI:10.1093/abbs/gmab071] [PMID]
29. Zheng JJ, Du XJ, Wang HP, Zhou LY, Wang YJ, Zhang L, et al. Long non-coding RNA 00152 promotes cell proliferation in cervical cancer via regulating miR-216b-5p/HOXA1 axis. Eur Rev Med Pharmacol Sci. 2019;23(9):3654-63.
30. Moradi MT, Hatami R, Rahimi Z. Circulating CYTOR as a Potential Biomarker in Breast Cancer. Int J Mol Cell Med. 2020;9(1):83-90.
31. Lu Q, Wang L, Gao Y, Zhu P, Li L, Wang X, et al. lncRNA APOC1P1-3 promoting anoikis-resistance of breast cancer cells. Cancer Cell Int. 2021;21(1):232. [DOI:10.1186/s12935-021-01916-w] [PMID] [PMCID]
32. Liao XH, Wang JG, Li LY, Zhou DM, Ren KH, Jin YT, et al. Long intergenic non-coding RNA APOC1P1-3 inhibits apoptosis by decreasing alpha-tubulin acetylation in breast cancer. Cell Death Dis. 2016;7:e2236. [DOI:10.1038/cddis.2016.142] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
